| Summary of royalty and commercial payment receivable and contingent consideration activities |
The following table summarizes the royalty and commercial payment receivable activities under the cost recovery method during the year ended December 31, 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2024 |
|
|
Acquisition of Royalty and Commercial Payment Receivables |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Recognition of Contingent Consideration |
|
|
Credit Losses on Purchased Receivables |
|
|
Reclassification of Royalty and Commercial Payment Receivables from the Cost Recovery to the EIR Method |
|
|
Balance as of December 31, 2024 |
Twist |
|
$ |
— |
|
$ |
15,000 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
$ |
15,000 |
Daré |
|
|
— |
|
|
22,000 |
|
|
(1) |
|
|
— |
|
|
— |
|
|
— |
|
|
21,999 |
Talphera |
|
|
— |
|
|
8,000 |
|
|
(96) |
|
|
— |
|
|
(7,904) |
|
|
— |
|
|
— |
LadRx |
|
|
6,000 |
|
|
— |
|
|
(2,150) |
|
|
1,000 |
|
|
— |
|
|
— |
|
|
4,850 |
Aptevo |
|
|
7,976 |
|
|
— |
|
|
(795) |
|
|
— |
|
|
— |
|
|
(7,181) |
|
|
— |
Agenus |
|
|
14,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
(14,000) |
|
|
— |
|
|
— |
Aronora |
|
|
9,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
(9,000) |
|
|
— |
|
|
— |
Palobiofarma |
|
|
10,000 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
10,000 |
Viracta |
|
|
8,500 |
|
|
— |
|
|
(8,500) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Kuros |
|
|
4,500 |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
4,500 |
Affitech |
|
|
12,191 |
|
|
— |
|
|
(7,396) |
|
|
3,000 |
|
|
— |
|
|
(7,795) |
|
|
— |
Total |
|
$ |
72,167 |
|
$ |
45,000 |
|
$ |
(18,938) |
|
$ |
4,000 |
|
$ |
(30,904) |
|
$ |
(14,976) |
|
$ |
56,349 |
The following table summarizes the contingent consideration under RPAs, AAAs, and CPPAs activities during the year ended December 31, 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2024 |
|
|
Recognition of Contingent Consideration |
|
|
Payment of Contingent Consideration |
|
|
Balance as of December 31, 2024 |
Contingent Consideration under ASC 450: |
|
|
|
|
|
|
|
|
|
|
|
|
Affitech |
|
$ |
6,000 |
|
$ |
3,000 |
|
$ |
(6,000) |
|
$ |
3,000 |
LadRx |
|
|
— |
|
|
1,000 |
|
|
(1,000) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent Consideration under ASC 815: |
|
|
|
|
|
|
|
|
|
|
|
|
LadRx |
|
|
1,000 |
|
|
— |
|
|
(1,000) |
|
|
— |
Total |
|
$ |
7,000 |
|
$ |
4,000 |
|
$ |
(8,000) |
|
$ |
3,000 |
The following table summarizes the royalty and commercial payment receivable activities under the EIR method during the year ended December 31, 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1, 2024 |
|
|
Reclassification of Royalty and Commercial Payment Receivables from the Cost Recovery to the EIR Method |
|
|
Income from Purchased Receivables Under the EIR Method |
|
|
Receipt of Royalty and Commercial Payments |
|
|
Balance as of December 31, 2024 |
Affitech |
|
$ |
— |
|
$ |
7,795 |
|
$ |
14,800 |
|
$ |
(9,490) |
|
$ |
13,105 |
Aptevo |
|
|
— |
|
|
7,181 |
|
|
266 |
|
|
(819) |
|
|
6,628 |
Total |
|
$ |
— |
|
$ |
14,976 |
|
$ |
15,066 |
|
$ |
(10,309) |
|
$ |
19,733 |
|